Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JGA Compiles Model Corporate Ethics Standards
August 1, 2011
- Takeda to Beef Up Its OTC Drugs Business in Asia
August 1, 2011
- RaQualia Listed on JASDAQ; Aims to Raise ¥6.3 Bil.
August 1, 2011
- MTPC Ordered to Stop Operations for 10 Days at Subsidiary Plant
August 1, 2011
- Japan Federation of Non-prescription Medicines Industry Set Up by 5 Organizations
August 1, 2011
- Astellas to Drive Business in Emerging Markets Based on GCL Strategy: Vice Deputy Chairman Ishii
August 1, 2011
- Council Starts Discussing How to Realize Proposed Social Security/Tax Reform Plan
August 1, 2011
- 3 Vaccines Judged to Be Safe “at Present Time”: PAFSC Study Groups
August 1, 2011
- Chugai: Operating Profits Up 27% in 1st Half
August 1, 2011
- EMA Asks Takeda to Revise Package Inserts for Pioglitazone Medicines Due to Risk of Bladder Cancer
August 1, 2011
- PAFSC Subcommittee Recommends Classification of 4 Crude Drugs as Class 2 OTC Drugs
August 1, 2011
- Taiho Ties Up with Nordic Group to Commercialize TS-1 in Europe
August 1, 2011
- PMDA Establishes Coordinating Organization to Prepare for PIC/S Membership
August 1, 2011
- Eisai's Halaven “Extremely Convenient for Outpatients”: Dr Iwata of Aichi Cancer Center
August 1, 2011
- Equa Ranked No. 1 Both in HP, GP Markets for 2nd Straight Month: RepTrack Survey
August 1, 2011
- Generic Drugmakers Still Reluctant to File for Add'l Indications Based on Info in Public Domain
August 1, 2011
- JPA Urges Member Pharmacies to Participate in JCQHC-initiated Accident Reporting Project
August 1, 2011
- Japanese Pharm. Industry Needs Aggressive Globalization: Dr Kato of EFPIA Japan
August 1, 2011
- Premium for New Drug Development Should Be Made Permanent: Mr Wolf of PhRMA
August 1, 2011
- Asahi Kasei to Enter Market for Medical Devices for Emergency Care Aiming at ¥100 Bil. Sales
August 1, 2011
ページ
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…